A practical reference on Tesamorelin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-22. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Abacus – The Aztec and Maya of Mesoamerica performed arithmetic operations using an abacus. It served as a more accurate and faster alternative to a written solution or relying on memory. Archaeologists have recorded the Mesoamerican abacus, or Nepohualtzintzin, as being present in Mesoamerica from at least between 900 and 1000 CE. Abstract art – Abstract art was used by nearly all societies of North and South America. Members of European art world believed tribal art was "primitive" until the 1890s when it served as inspiration for the modern American abstract art movement. See also Visual arts by indigenous peoples of the Americas.
fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) or glucose tolerance test with two hours after the oral dose a plasma glucose ≥ 11.1 mmol/L (200 mg/dL) A random blood sugar of greater than 11.1 mmol/L (200 mg/dL) in association with typical symptoms or a glycated hemoglobin (HbA1c) of ≥ 48 mmol/mol (≥ 6.5 DCCT %) is another method of diagnosing diabetes. In 2009, an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a HbA1c threshold of ≥ 48 mmol/mol (≥ 6.5 DCCT %) should be used to diagnose diabetes. This recommendation was adopted by the American Diabetes Association in 2010. Positive tests should be repeated unless the person presents with typical symptoms and blood sugar >11.1 mmol/L (>200 mg/dL).
=== Peru === Joseph Dombey, in a letter written from Lima on 20 May 1779, specifies the ancestral way used by the Peruvians to prepare potatoes that constitute, along with maize (U.S.: "corn"), their primary foods. Further, that they carry potatoes in haversacks on long journeys, for which the potato is prepared by cooking it in water, then peeling it, and finally exposing it to the wind and sun until it has completely dried. The process can preserve it "several centuries, by guaranteeing it of the humidity". This papa seca (dried potato) is then mixed in with other foods to make meals. Another process consists of freezing the potato and treading on it to remove the skin. Thus prepared, it is put in running water and loaded with stones. Fifteen or twenty days later, it is exposed to the sun until it dries. It becomes the chuño, "a real starch, with which one could make powder for the hair". The Peruvians use it to prepare jams, a flour for convalescents, and mix it with almost all their dishes. An author of the 20th century points out that the process of the Peruvians, who operate by freezing followed by dehydration, is none other than "a freeze-drying by the natural means". He specifies that the tubers are left in frozen water several nights before being exposed to the sun and trodden on and that, "to make the product suitable for consumption, it is enough to put it back in water". According to him, the Spaniards used this preparation in the 16th century to feed the indigenous people forced to work in the silver mines of Potosi.
== Further reading == Aziz, Nusrate; Asadullah, M Niaz (2017). "Military spending, armed conflict and economic growth in developing countries in the post–Cold War era". Journal of Economic Studies. 44 (1): 47–68. Bartel, Fritz (2022). The Triumph of Broken Promises: The End of the Cold War and the Rise of Neoliberalism. Harvard University Press. ISBN 9780674976788. Henriksen, Thomas H. (2017). Cycles in US Foreign Policy Since the Cold War. Palgrave Macmillan. Jones, Bruce D.; Stedman, Stephen John (2017). "Civil Wars & the Post–Cold War International Order". Dædalus. 146 (4): 33–44. Menon, Rajan; Rumer, Eugene B., eds. (2015). Conflict in Ukraine: The Unwinding of the Post–Cold War Order. MIT Press. Peterson, James W. (2017). Russian-American relations in the post–Cold War world. Oxford UP. Sakwa, Richard (2017). Russia against the Rest: The Post–Cold War Crisis of World Order. Cambridge UP. p. 362. Wood, Luke B. (2017). "The politics of identity and security in post–Cold War Western and Central Europe". European Politics and Society. 18 (4): 552–556.
Sources: en.wikipedia.org
== Preceding viral infections == A number of different preceding viral infections have been reported, most commonly influenza A and B. The condition appears to be more prevalent during late fall, winter, and spring. Other virus infections that have been linked to BACM are those caused by Parainfluenza, Coxsackievirus, Adenovirus, Echovirus, and Mycoplasma pneumonia. Viral myositis after viral infections may also occur in adults, and viruses, such as COVID-19, have been reported as a rare cause of myositis.
=== September === September 1 Following reports of tensions with US Defense Secretary Pete Hegseth, US Army Secretary Daniel P. Driscoll steps down. The U.S. announces that it struck IRGC targets in Iran after the latter's attacks on commercial shipping in Hormuz and its soldiers, adding that it targeted tankers owned by the National Iranian Oil Company as part of its new "tanker to tanker" policy. Trump states that a most devastating attack is in the works, adding that when it is complete the Iranian government will be in ruins. Trump announces that a major target of those strikes were Iran's efforts to rebuild its radar system. Over $560,000 in cryptocurrency donations for Hamas are seized by the Justice Department. LGBTQ rights in the United States: The Department of Justice files a lawsuit against the Kansas City Public Schools district over its policies that allow transgender students to share their preferred name, gender, and pronouns with school staff. September 2 Birthright citizenship in the United States: American federal judge Deborah Boardman of the U.S. District Court for the District of Maryland blocks an attempt by the Trump administration to implement an executive order aimed at ending birthright citizenship in the United States. Hegseth extends the deployments of approximately 50,000 American soldiers in West Asia, which include warship crews, air defense units, and paratroopers, until 2027. September 3 Chipmaker Nvidia agrees to buy the Hugging Face AI platform in a deal worth $12.9 billion.
Immunomodulating agents regulate the immune system's response and are produced by various immune cells. These agents include the following agents and markers: The BCG vaccine has been used against tuberculosis, mycobacteria, and various cancers in the form of vaccination as an initial immune system stimulant. In cancer, the anti-tumor immunological effects are elicited by the host's immune response and the BCG infection against the tumor cells, most commonly in bladder cancer. The immune activation allows for further recognition and elimination of malignant tumor cells. Specific active immunotherapy administers a specific antigen as the therapy. The therapy allows the host to create an antigen-specific response with the development of antibodies, proliferation of cytotoxic T lymphocyte responses, or both, directed at the desired pathogen or malignant tumor cell in the case of cancer therapy.
1 element (tin) has 10 stable isotopes 5 elements have 7 stable isotopes apiece 7 elements have 6 stable isotopes apiece 11 elements have 5 stable isotopes apiece 9 elements have 4 stable isotopes apiece 5 elements have 3 stable isotopes apiece 16 elements have 2 stable isotopes apiece 26 elements have 1 single stable isotope. These last 26 are thus called monoisotopic elements. The mean number of stable isotopes for elements which have at least one stable isotope is 251/80 = 3.1375.
=== Brand names === Glibenclamide is available as a generic medication, is manufactured by many pharmaceutical companies and is sold under many brand names including Gliben-J, Daonil, Diabeta, Euglucon, Gilemal, Glidanil, Glybovin, Glynase, Maninil, Micronase and Semi-Daonil. It is also available in a fixed-dose combination drug with metformin that is sold under various trade names, e.g. Bagomet Plus, Benimet, Glibomet, Gluconorm, Glucored, Glucovance, Metglib and many others.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.